New research at Kansas State University aims to tackle one of the most significant threats to global animal health and food security — highly pathogenic avian influenza, or HPAI — by using mealworms, ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo ...

Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 ...

Animal Genetics Market OverviewThe Animal Genetics Market is anticipated to grow at a CAGR of 6–7% between 2023 and 2028. This upward trajectory is driven by several influential factors, including the ...

Scientists fed Aedes aegypti mosquitoes blood laced with weakened rabies and Nipah viruses, then let those insects bite bats ...

Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticip ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will ...

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.